Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center)

N/A

Report date: 2026/03/19 16:46:56

Base Information

Drug NameAnti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center)
Drug Alias NameBispecific antibody-armed activated T cells抗EGFR双特异性抗体武装的活化T细胞疗法-斯隆-凯特琳癌症中心Bispecific antibody-armed activated T cell therapyAnti-EGFR-bispecific antibody armed activated T-cellsAnti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > T cell engagers
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsCD3 T-cell engagersT lymphocyte replacements
TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A